---
title: "Biocytogen, Whitehawk Therapeutics team up on bispecific antibody-drug conjugate development"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291929980.md"
description: "Whitehawk Therapeutics and Biocytogen have entered a global collaboration to develop bispecific antibody-drug conjugates (BsADCs) for oncology. Biocytogen will supply up to five fully human bispecific antibodies from its RenLite platform, which Whitehawk will evaluate using its ADC linker-payload technologies. Whitehawk holds the option to advance candidates, securing global rights upon exercise. Biocytogen receives an upfront payment, development milestones, regulatory/commercial milestones, and low single-digit royalties."
datetime: "2026-07-07T12:07:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291929980.md)
  - [en](https://longbridge.com/en/news/291929980.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291929980.md)
---

# Biocytogen, Whitehawk Therapeutics team up on bispecific antibody-drug conjugate development

-   Whitehawk Therapeutics entered a global collaboration with Biocytogen to develop bispecific antibody-drug conjugates for oncology. \* Biocytogen will supply up to five fully human bispecific antibodies from its RenLite platform for evaluation with Whitehawk’s ADC linker-payload technologies. \* Whitehawk holds an option to advance resulting BsADC candidates, taking global rights and full program control if exercised. \* Biocytogen will receive an upfront payment, milestones tied to development, regulatory and commercial events, and low single-digit royalties on net sales. \* Whitehawk targets new ADC IND filings within 12-24 months, using the collaboration to expand its pipeline. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [WHWK.US](https://longbridge.com/en/quote/WHWK.US.md)
- [02315.HK](https://longbridge.com/en/quote/02315.HK.md)
- [688796.CN](https://longbridge.com/en/quote/688796.CN.md)

## Related News & Research

- [Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload | WHWK Stock News](https://longbridge.com/en/news/287273221.md)
- [Akari Therapeutics enters strategic ADC payload research collaboration with Whitehawk Therapeutics](https://longbridge.com/en/news/293474953.md)
- [Lee’s Pharma says China NMPA accepts IND filing for ADC candidate ZK2401](https://longbridge.com/en/news/294379955.md)
- [Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestone](https://longbridge.com/en/news/293970382.md)
- [How Investors Are Reacting To Agree Realty (ADC) Earnings Growth Outpacing Diluted EPS Gains](https://longbridge.com/en/news/294685655.md)